<DOC>
	<DOCNO>NCT00317369</DOCNO>
	<brief_summary>The purpose study examine safety efficacy OPC-6535 determine optimal dose once-daily oral administration 0 , 25 , 50 mg 8 week combination fix oral dose 5-aminosalicylic acid ( 5-ASA ) combination fix oral dose 5-ASA enteral nutrition patient active Crohn 's disease .</brief_summary>
	<brief_title>A Dose-Finding Study OPC-6535 Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients active Crohn 's disease Patients primary lesion either small intestine large intestine Patients receive oral 5ASA formulation fix regimen fix dose Patients either never receive enteral nutrition receive enteral nutrition fix intake 1200 kcal/day le Either inpatient outpatient Patients external fistula ( include anal fistula ) persistent drainage observe ( require treatment antibiotic synthetic antibacterial agent ) Patients short bowel syndrome ( require intravenous nutritional support due insufficient intestinal nutrient uptake ) Patients artificial anus Patients complication serious infectious disease ( intraabdominal abscess , etc . ) Patients complication malignant tumor Female patient pregnant , lactate , possibly pregnant , wish become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>OPC-6535</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>